Management of epidermal growth factor receptor tyrosine kinase inhibitor‐related cutaneous and gastrointestinal toxicities

Publisher： John Wiley & Sons Inc

E-ISSN： 1743-7563|14|1|23-31

ISSN： 1743-7555

Source： ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol.14, Iss.1, 2018-02, pp. : 23-31

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rebiopsy of non–small cell lung cancer patients with acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor

By  

CANCER, Vol. 119, Iss. 24, 2013-12 ,pp. : 4325-4332

John Wiley & Sons Inc

Access to resources Recommend Favorite

Should Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Be Continued beyond Progressive Disease

By  

Case Reports in Oncology, Vol. 4, Iss. 3, 2011-09 ,pp. : 470-474

Karger

Access to resources Recommend Favorite

The Epidermal Growth Factor Receptor Inhibitor-Related Skin Toxicity Index (EGFRISTI): A New Tool for Grading and Managing Skin Adverse Reactions to Epidermal Growth Factor Receptor Inhibitors

By  

Oncology, Vol. 87, Iss. 5, 2014-08 ,pp. : 311-319

Karger

Access to resources Recommend Favorite

Management of the Cutaneous Side Effects of Therapeutic Epidermal Growth Factor Receptor Inhibition

By  

Oncology Research and Treatment, Vol. 33, Iss. 8-9, 2010-07 ,pp. : 470-479

Karger

Access to resources Recommend Favorite

The Epidermal Growth Factor Receptor in Breast Cancer: EGF-Related Peptides and Their Type I Receptor Tyrosine Kinases

By Fox Stephen B.   Harris Adrian L.  

Journal of Mammary Gland Biology and Neoplasia, Vol. 2, Iss. 2, 1997-04 ,pp. : 131-141

Springer Publishing Company

Access to resources Recommend Favorite